Identification of atrophy of the subgenual anterior cingulate cortex, in particular the subcallosal area, as an effective auxiliary means of diagnosis for major depressive disorder

Background: Despite being a very common psychiatric disorder, physicians often have difficulty making a diagnosis of major depressive disorder (MDD) because, without established diagnostic criteria, they have to depend on interviews with patients and observation to assess psychiatric symptoms. However, previous researchers have reported that magnetic resonance imaging (MRI) scans identify morphological changes in the brains of patients with MDD, which inspired us to hypothesize that assessment of local changes in the brain using voxel-based morphometry would serve as an auxiliary diagnostic method for MDD. Therefore, we focused on the VSRAD® plus (voxel-based specific regional analysis system for Alzheimer’s disease), a diagnostic support system for use in early Alzheimer’s disease, which allowed us to identify regional atrophy in the brain easily based on images obtained from MRI scans.

Methods: The subjects were 75 patients with MDD, 15 with bipolar disorder, and 30 healthy subjects, aged 54–82 years. First, 1.5 T MRI equipment was used to scan three-dimensional T1-weighted images for the individual subjects, and the imaged data were analyzed by VSRAD advance (voxel-based morphometric software developed for diagnosis of early Alzheimer’s disease). The efficacy of the equipment for diagnosis of MDD was evaluated based on the distribution of atrophy in the subgenual anterior cingulate cortex (sACC) on the z-score map obtained.

Results: No significant difference in atrophy was noted between the left and right sACCs. The VSRAD advance used in the present study was more effective than the VSRAD plus for diagnosis of MDD, with a sensitivity of 90.7%, specificity of 86.7%, accuracy of 89.5%, a positive predictive value of 94.4%, and a negative predictive value of 78.8%. In particular, atrophy was observed in the subcallosal area of the sACC.

Conclusion: The identification of atrophy in the sACC, in particular of the subcallosal area, with the use of updated voxel-based morphometric software proved to be effective as an auxiliary diagnostic method for MDD.

Keywords: major depressive disorder, magnetic resonance imaging, subgenual anterior cingulate cortex, voxel-based morphometry, VSRAD

Introduction

Major depressive disorder (MDD) is a very common psychiatric disorder, with a lifetime prevalence of approximately 20%. When making a diagnosis of MDD, psychiatrists usually interview patients or observe them to assess their psychiatric symptoms although, without established visual diagnostic criteria, they often have difficulty.
In recent years, studies have been conducted involving the local morphology and function of the brain using magnetic resonance imaging (MRI), single-photon emission computed tomography, and positron emission tomography, as well as genetic research. However, few studies have been performed in the clinical setting, and there is no established method for auxiliary diagnosis of MDD.

We hypothesized that assessment of local morphological changes in the brain might serve as an auxiliary diagnostic method for MDD. Using a voxel-based specific regional analysis system for Alzheimer’s disease (VSRAD* plus, Eisai Co, Ltd, Tokyo, Japan), which was developed based on the voxel-based morphometry method and is now freely available,1–4 we investigated the subgenual anterior cingulate cortex (sACC), amygdala, hippocampus, and prefrontal area, reported to be associated with MDD in earlier studies,5–23 and made the following observations. Atrophy of the sACC was noted in 65 of 71 MDD patients, and the prevalence was higher than that observed in the hippocampus, amygdala, and prefrontal area (in 35, 21, and 20 patients, respectively). The sensitivity, specificity, and accuracy of the diagnosis of MDD based on the presence or absence of atrophy in the sACC was 93%, 85%, and 90%, respectively.2 Accordingly, we suggested that identification of atrophy in the sACC (including a part of the orbitofrontal area) would be useful for accurate auxiliary diagnosis of MDD.

In the present study, using VSRAD advance updated by incorporating statistical parametric mapping (SPM8, Wellcome Department of Imaging Neuroscience, London, UK) and diffeomorphic anatomic registration through an exponentiated lie algebra (DARTEL, Wellcome Department of Imaging Neuroscience),24 we investigated the usefulness of identifying the presence or absence of atrophy in the sACC for diagnosis of MDD.

Materials and methods

The study was conducted with the approval of the hospital ethics committee. The purpose of the study was explained to all subjects verbally and in written form, and their informed consent was obtained.

The subjects comprised 120 examinees at the psychiatric clinics aged 54–82 years. This age range was indicated for VSRAD advance because the database included in the software program contained data from healthy volunteers in this age range. The subjects were divided into three groups. One group comprised 75 patients with MDD diagnosed by a psychiatrist based on the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV), and included nine males and 66 females of mean age 66.3 ± 7.6 years. Patients with cognitive dysfunction were excluded. The second group comprised 15 patients with bipolar disorder diagnosed according to the DSM-IV, and included seven males and eight females of mean age 63.1 ± 4.8 years. The third group comprised 30 healthy subjects with no past medical history of MDD who underwent MRI to exclude organic disease, and included six males and 24 females of mean age 65.8 ± 5.4 years. The gender ratio was significantly different between the groups, but no significant difference was noted for subject age. Disease severity based on the Hamilton Rating Scale for Depression was 12–31 (mean 19.3 ± 3.4) in the 75 patients in the MDD group; this score was lower than 13 in one patient, 14–18 in 42, 19–22 in 13, and ≥23 in 19. The duration of illness was 0.9–10 (mean 4.9 ± 2.7) years; ≤0.5 years in 0 patients, 0.6–1 year in 10, 1.1–3 years in 22, 3.1–6 years in 19, and ≥6.1 years in 24. The duration of treatment was 0.5–9 (mean 3.4 ± 2.5) years, ≤0.5 years in seven patients, 0.6–1 year in 18, 1.1–3 years in 19, 3.1–6 years in 18, and ≥6.1 years in 13 patients. In the bipolar disorder group comprising 15 patients, the mean duration of disease was 11.5 ± 3.2 years, which was slightly longer than that in the MDD group. The mean duration of treatment was 6.2 ± 4.0 years, showing no significant difference from that in the MDD group (Table 1). Only mild nonmorbid lesions in the white matter were noted on T1-weighted imaging, and no cases of cerebral infarction were detected.

All the subjects were scanned using a 1.5 T Achieva Nova MRI system (Philips Healthcare, Eindhoven, The Netherlands) and a T1-weighted fast field echo sequence was used (field of view, 240 mm; matrix, 256 × 256; repetition time, 9.3 msec; echo time, 4.3 msec; flip angle, 10°; slice thickness, 2 mm, with 1 mm slices superimposed). A total of 160 T1-weighted three-dimensional sagittal sections of the brains were acquired. The acquisition time was 3 minutes and 35 seconds. The Digital Imaging and Communication in Medicine data obtained were automatically analyzed on a PC using the VSRAD advance program. First, equalization of voxel sizes and linear and nonlinear transformations were performed. Next, images of gray matter, white matter, and cerebrospinal fluid were separated, and the gray matter images were standardized and smoothed onto templates using DARTEL. Finally, using the z-score analysis method, comparative statistical analysis of the voxels was performed for healthy control and subject databases:

\[ \text{z-score} = ((\text{control mean}) - \text{[individual value]})/\text{(control standard deviation)} \]
The database for the healthy controls contained data from 40 males and 40 females each aged 54–86 (mean 70.2 ± 7.3) years. Their z-score maps were displayed in color on seismic tomographic and standardized surface-rendering images (Figure 1).

The sACC (parts of Brodmann areas 24, 32, and 33) on the surface-rendering images was set as the area of interest to identify atrophy, and colored areas in the left and right sACCs were determined as atrophic lesions. For diagnosis of Alzheimer’s disease, areas are displayed in color when the z-score is ≥2, ie, a threshold or risk rate of P, 0.05 in comparison with the database for healthy controls. In this study, receiver operating characteristic analysis was done to confirm the validity of the score in MDD diagnosis. The presence or absence of atrophy in the sACC was compared based on the presence or absence of a color-displayed area on the z-score map for the patients with MDD or bipolar disorder and for the healthy subjects. We then investigated VSRAD plus and VSRAD advance for their performance as diagnostic tools in MDD.

**Results**

Receiver operating characteristic analysis for the VSRAD advance confirmed the validity of a z-score of 2.0 as the threshold for color display on the z-score maps. No significant difference was noted in the area under the curve on receiver operating characteristic analysis between the VSRAD plus and the VSRAD advance (Figure 2). Diagnoses using the VSRAD advance identified atrophy in the sACC in 68 (63 on the left side and 65 on the right side) of the 75 patients with MDD, with no significant difference between the left and right sACCs. Bilateral atrophy of the sACC was noted in one of the 15 patients with bipolar disorder. Atrophy was noted in four (four each on the left and right sides) of the 30 healthy subjects, with no difference between the left and right sACCs. Using the VSRAD plus, atrophy was identified in 62 of the 75 patients with MDD, six of the 15 patients with bipolar disorder, and five of the 30 healthy subjects. No lateralization was noted in atrophy of the sACC in any group. Significant differences were noted in the sACC atrophy rate detected using either the VSRAD advance or VSRAD plus between the MDD and bipolar disorder groups and between the MDD and healthy subject groups (Table 2). Moreover, with the VSRAD advance, no correlation was noted between atrophy of the sACC and disease severity, duration of illness, or duration of treatment. Regarding the accuracy of MDD diagnosis in comparison with healthy subjects, the VSRAD advance had a sensitivity of 90.7%, specificity of 86.7%,
accuracy of 89.5%, a positive predictive value (PPV) of 94.4%, and a negative predictive value (NPV) of 78.8%, which was markedly higher compared with the VSRAD plus, which showed a sensitivity, specificity, accuracy, PPV, and NPV of 82.7%, 83.3%, 82.9%, 92.5%, and 65.8%, respectively (Table 3).

The shapes of the colored areas superimposed on the z-score maps were classified into four patterns. The first was a dot pattern displayed on the subcallosal area of the sACC (parts of Brodmann areas 24, 32, and 33). This pattern was noted in ten of the 68 patients with MDD who presented with atrophy of the sACC. The second one, a linear pattern that presents itself on the subcallosal area of the sACC, was identified in 14 patients. The third one, a massive pattern on the sACC (including the subcallosal area), was observed in 24 patients. The fourth pattern, which is usually observed in the medial prefrontal area, including the sACC, was noted in 20 patients (Table 4 and Figure 3).

In summary, in all cases in which atrophy of the sACC was noted, atrophy of the subcallosal area of the sACC was identified. These results suggest that the identification of atrophy of the subcallosal area of the sACC is important.
Discussion

Although there have been several studies conducted on atrophy of the subgenual cingulate cortex in MDD, few of them have been used in the clinical setting. In previous research, we have focused on the VSRAD plus, an early diagnostic support system for Alzheimer’s disease, which allowed us to identify regional atrophy in the brain easily, based on images obtained from MRI scans. We showed that identification of atrophy of the sACC (through a visual method) served as an effective auxiliary means of diagnosis for MDD.

In the present study, we used the VSRAD advance, a voxel-based morphometry-based software for the automatic detection of specific atrophy in early Alzheimer’s disease upgraded with the SPM8 and DARTEL, for distinguishing patients with MDD from healthy subjects. The sensitivity was 90.7%, and the specificity, accuracy, PPV, and NPV were 86.7%, 89.5%, 94.4%, and 78.8%, respectively. The accuracy of the VSRAD advance was markedly higher compared with that of the VSRAD plus. This was presumably attributed to the newly adopted algorithms, which allowed the SPM8 to isolate gray matter images more efficiently, as well as the more accurate anatomical standardization onto templates by DARTEL.

Given that the number of healthy subjects was limited at the outpatient clinics, further investigation involving more healthy volunteers is awaited for accuracy of the PPV and NPV. Nevertheless, the results are still useful for comparison of the plus and advance methods.

In this study, there were massive and spreading forms of atrophy in the sACC, and dot and linear forms of atrophy were particularly noted in the subcallosal area of the sACC. In all cases in which atrophy of the sACC was noted, atrophy of the subcallosal area of the sACC was identified. In 48 of the 68 cases, as the threshold for the z-score maps was lowered, colored areas first started to appear in the subcallosal area of the sACC, and atrophy was extensive in this area, suggesting that the presence or absence of atrophy of the subcallosal area of the sACC has a significant meaning in the diagnosis of MDD.

Table 2 Atrophy of sACC of VSRAD plus vs VSRAD advance

<table>
<thead>
<tr>
<th>Application</th>
<th>VSRAD plus</th>
<th>VSRAD advance</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDD (n = 75)</td>
<td>62 (83%)</td>
<td>68 (91%)</td>
</tr>
<tr>
<td>Right</td>
<td>NS</td>
<td>P &lt; 0.001</td>
</tr>
<tr>
<td>Left</td>
<td>NS</td>
<td>P &lt; 0.001</td>
</tr>
<tr>
<td>BD (n = 15)</td>
<td>5 (33%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Right</td>
<td>P &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>P &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>HC (n = 30)</td>
<td>5 (17%)</td>
<td>4 (13%)</td>
</tr>
<tr>
<td>Right</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Left</td>
<td>3 (10%)</td>
<td>4 (13%)</td>
</tr>
</tbody>
</table>

Abbreviations: BD, bipolar disorder; HC, healthy controls; MDD, major depressive disorder; NS, no significant difference; sACC, subgenual anterior cingulate cortex; VSRAD, Voxel-based Specific Regional analysis system for Alzheimer’s Disease.

Table 3 Diagnostic proportion of MDD vs HC

<table>
<thead>
<tr>
<th></th>
<th>VSRAD plus (%)</th>
<th>VSRAD advance (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>82.7</td>
<td>90.7</td>
</tr>
<tr>
<td>Specificity</td>
<td>83.3</td>
<td>86.7</td>
</tr>
<tr>
<td>Accuracy</td>
<td>82.9</td>
<td>89.5</td>
</tr>
<tr>
<td>PPV</td>
<td>92.5</td>
<td>94.4</td>
</tr>
<tr>
<td>NPV</td>
<td>65.8</td>
<td>78.8</td>
</tr>
</tbody>
</table>

Abbreviations: HC, healthy controls; MDD, major depressive disorder; NPV, negative predictive value; PPV, positive predictive value; VSRAD, Voxel-based Specific Regional analysis system for Alzheimer’s Disease.

Table 4 The shapes of colored areas on cortical surface of the standardized MRI template

<table>
<thead>
<tr>
<th>Shape</th>
<th>n = 68</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dot</td>
<td>10</td>
</tr>
<tr>
<td>Line</td>
<td>14</td>
</tr>
<tr>
<td>Massive</td>
<td>24</td>
</tr>
<tr>
<td>Wide-spread</td>
<td>20</td>
</tr>
</tbody>
</table>
The results of the present study suggest that the VSRAD advance, providing more accurate diagnosis including sensitivity, accuracy, and NPV, is effective as an auxiliary diagnostic method for MDD with a high degree of accuracy. When using this method in clinical practice, careful attention should be paid to the following points. There was only a slight increase in specificity and PPV, which would indicate that some healthy subjects also have atrophy of the sACC. In other words, atrophy of the sACC is also noted in those other than patients with MDD. What then does atrophy of the sACC mean? Previous investigators reported atrophy of the subgenual cingulate cortex and amygdala in carriers of the s allele for serotonin transporter polymorphism.29 Another study has reported that a larger percentage of carriers of s allele polymorphism who had undergone four or more stressful life events over the past five years developed depression compared with l/l-type carriers.30 There is also a report that no significant differences were noted in cingulate volumes between currently depressed and remitted patients.31 There was no marked difference in the level of atrophy in nine MDD patients with atrophy of the sACC re-examined after a period of 302–546 (mean 476 ± 55.5) days.

According to these reports, atrophy of the sACC is genetically determined, and it indicates a carrier of an s allele polymorphism or vulnerability to depression. Atrophy of the subgenual cingulate cortex observed in young patients with MDD may add to its evidence.25 Therefore, this method serves to diagnose vulnerability to depression rather than MDD itself. When atrophy of the sACC is not identified in a patient complaining of depressive symptoms following an MRI examination in daily clinical practice, we can determine that the patient will be responsive to antidepressant medication or consider the possibility of other diseases.4 Nevertheless, the fact that atrophy of the sACC is not noted can be valuable clinical information in addition to medical interviews and observation.

Figure 3  z-score maps of patients with major depressive disorder (A) for a 70-year-old woman and (B) for a 71-year-old woman. Colored areas in dot-like form are overlaid on the cortical surface of the subgenual anterior cingulate cortex displayed on a standardized MRI template (arrows). (C) Images for a 57-year-old woman and (D) for a 59-year-old woman. Colored areas in linear form are overlaid on the subgenual anterior cingulate cortex (arrows). (E) Image for a 62-year-old woman and (F) for a 68-year-old woman. Colored areas in massive form are overlaid on the subgenual anterior cingulate cortex (arrows). (G) Image for a 72-year-old woman and (H) for a 58-year-old woman. Colored areas in spreading form are overlaid on the subgenual prefrontal cortex including the subgenual anterior cingulate cortex (arrows).
In order to improve the objectivity of the method, it is necessary to specify the volume of interest and calculate the mean z-score and rate of atrophy within the area as well as the ratio of atrophy to that in the whole brain. It is also necessary to collect data from a large number of health care facilities to determine acceptable margins among different institutions and equipment.

With improvement designed to specify automatically the volume of interest and calculate the mean volume of interest z-score and rate of atrophy within the area as well as the ratio to atrophy in the whole brain, the auxiliary diagnostic method would be even simpler and more effective.

**Conclusion**

The present study examined the effectiveness of identification of atrophy in the sACC with VSRAD advance, upgraded with SPM8 and DARTEL, as a diagnostic method for MDD. It was suggested that the simple auxiliary method for the diagnosis of MDD was effective for distinguishing patients with MDD from healthy subjects, and the sensitivity, specificity, accuracy, and PPV values were 90.7%, 86.7%, 89.5%, and 94.4%, respectively. In patients with MDD, atrophy was identified in localized areas of the subcallosal area in the sACC (parts of Brodmann areas 24, 32, and 33), which suggests that identification of atrophy in the subcallosal area is important for the diagnosis of MDD.

**Acknowledgments**

The authors are indebted to Professor Scott Fraser for his valuable comments on the manuscript and constructive suggestions regarding this paper. We are also grateful to Takako Kuniyoshi from the Nanto Clinic for her encouragement and administrative support.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


